CA
SCNI

Calton & Associates’s Scinai Immunotherapeutics SCNI Stock Holding History

Calton & Associates’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2
Closed -$1K – 1103
2017
Q4 		$1K Buy
+2
New +$1.26K ﹤0.01% 1451

Other funds holding SCNI

II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Calton & Associates's SCNI Position: Q1 2018 in Review

Calton & Associates sold out of Scinai Immunotherapeutics (SCNI) in Q1 2018, closing a stake of 2 shares — an estimated $1K sold.

Calton & Associates first reported a position in SCNI in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 15 funds tracked by Wall St. Rank hold SCNI as of Q1 2018.

  • Calton & Associates reported no remaining Scinai Immunotherapeutics position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 2 Scinai Immunotherapeutics shares in Q1 2018, an estimated $1K.
  • Calton & Associates first reported a position in Scinai Immunotherapeutics in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's Scinai Immunotherapeutics position peaked at $1K in Q4 2017.
  • 15 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.